免疫学的技術と感染症のジャーナル

Prospect of CD52 Targeted Alemtuzumab in Treatment of CNS Demyelination in Multiple Sclerosis

Subhajit Dasgupta and Mausumi Bandyopadhyay

Prospect of CD52 Targeted Alemtuzumab in Treatment of CNS Demyelination in Multiple Sclerosis

The choice of humanized monoclonal antibody is a novel therapeutic approach for autoimmune relapsing remitting multiple sclerosis (RRMS). In addition to anti-alpha-4 integr in monoclonal antibody Natalizumab, introduction of CAMPATH-1 (Alemtuzumab) is a fairly new approach in MS research and clinical trials. The uniqueness of this monoclonal antibodyis that it depletes CD52 marker expressing circulatory T and B cells including monocytes and dendritic cells. However, it has no impact on progenitor cells. Thus, the use of Alemtuzumab has gained importance in delaying rejection in allograft during transplantation.